- call +1-201-465-4211
- email sales@mrinsights.biz
The anti-diabetics market includes drugs, which are used for treatment of diabetes mellitus and are also known as oral hypoglycemic/antihyperglycemic agents. The anti-diabetics market has grown tremendously in recent years with increasing prevalence of diabetes mellitus. Thus, systemic therapies for diabetes have become the focal point of attention due to the burgeoning diabetic population size, with diabetes affecting middle age groups and children across all income groups globally.
Scope of the Report:
This report focuses on the Anti-Diabetic Drugs in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
Some of the major drivers and opportunities for growth of this market include drug combinations of several agents such as sitagliptin and metformin and other drug combinations that are in different stages of clinical and pipeline development. Increase in the prevalence of diabetes and new product launches by major pharmaceutical companies re some of the key drivers for growth in this market. In 2015, Boehringer Ingelheim GmbH launched two new drugs (Synjardy & Glyxambi)for treatment of diabetes mellitus type II.
Some of the key opportunities for the antidiabetics include a strong pipeline for antidiabetics and entry of new players in the market, for instance, Novo Nordisk's diabetes drug’s Tresiba, and Ryzodeg received FDA approval in September 2015. Moreover, Boehringer Ingelheim GmbH has a strong pipeline for anti-diabetic drugs, such as Linagliptin which is a dipeptidyl peptidase (DPP) 4 inhibitor) for patients suffering from diabetes mellitus type II and high cardiovascular risk.
The worldwide market for Anti-Diabetic Drugs is expected to grow at a CAGR of roughly xx% over the next five years, will reach xx million US$ in 2023, from xx million US$ in 2017, according to a new GIR (Global Info Research) study.
Market Segment by Manufacturers, this report covers
Astra Zeneca
Boehringer Ingelheim
Eli Lilly
Johnson & Johnson
Merck
Novartis
Novo Nordisk
Sanofi
Teva Pharmaceutical Industries
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Biguanides
Sulfonylureas
Meglitinides
Thiazolidinediones
Dipeptidyl Peptidase IV Inhibitors
α-Glucosidase Inhibitors
Market Segment by Applications, can be divided into
Type I Diabetes
Type II Diabetes
Others
There are 15 Chapters to deeply display the global Anti-Diabetic Drugs market.
Chapter 1, to describe Anti-Diabetic Drugs Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Anti-Diabetic Drugs, with sales, revenue, and price of Anti-Diabetic Drugs, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Anti-Diabetic Drugs, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Anti-Diabetic Drugs market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Anti-Diabetic Drugs sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Market Overview
1.1 Anti-Diabetic Drugs Introduction
1.2 Market Analysis by Type
1.2.1 Biguanides
1.2.2 Sulfonylureas
1.2.3 Meglitinides
1.2.4 Thiazolidinediones
1.2.5 Dipeptidyl Peptidase IV Inhibitors
1.2.6 α-Glucosidase Inhibitors
1.3 Market Analysis by Applications
1.3.1 Type I Diabetes
1.3.2 Type II Diabetes
1.3.3 Others
1.4 Market Analysis by Regions
1.4.1 North America (United States, Canada and Mexico)
1.4.1.1 United States Market States and Outlook (2013-2023)
1.4.1.2 Canada Market States and Outlook (2013-2023)
1.4.1.3 Mexico Market States and Outlook (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy)
1.4.2.1 Germany Market States and Outlook (2013-2023)
1.4.2.2 France Market States and Outlook (2013-2023)
1.4.2.3 UK Market States and Outlook (2013-2023)
1.4.2.4 Russia Market States and Outlook (2013-2023)
1.4.2.5 Italy Market States and Outlook (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
1.4.3.1 China Market States and Outlook (2013-2023)
1.4.3.2 Japan Market States and Outlook (2013-2023)
1.4.3.3 Korea Market States and Outlook (2013-2023)
1.4.3.4 India Market States and Outlook (2013-2023)
1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)
1.4.4 South America, Middle East and Africa
1.4.4.1 Brazil Market States and Outlook (2013-2023)
1.4.4.2 Egypt Market States and Outlook (2013-2023)
1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)
1.4.4.4 South Africa Market States and Outlook (2013-2023)
1.4.4.5 Nigeria Market States and Outlook (2013-2023)
1.5 Market Dynamics
1.5.1 Market Opportunities
1.5.2 Market Risk
1.5.3 Market Driving Force
2 Manufacturers Profiles
2.1 Astra Zeneca
2.1.1 Business Overview
2.1.2 Anti-Diabetic Drugs Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Astra Zeneca Anti-Diabetic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.2 Boehringer Ingelheim
2.2.1 Business Overview
2.2.2 Anti-Diabetic Drugs Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Boehringer Ingelheim Anti-Diabetic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.3 Eli Lilly
2.3.1 Business Overview
2.3.2 Anti-Diabetic Drugs Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Eli Lilly Anti-Diabetic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.4 Johnson & Johnson
2.4.1 Business Overview
2.4.2 Anti-Diabetic Drugs Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Johnson & Johnson Anti-Diabetic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.5 Merck
2.5.1 Business Overview
2.5.2 Anti-Diabetic Drugs Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Merck Anti-Diabetic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.6 Novartis
2.6.1 Business Overview
2.6.2 Anti-Diabetic Drugs Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Novartis Anti-Diabetic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.7 Novo Nordisk
2.7.1 Business Overview
2.7.2 Anti-Diabetic Drugs Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Novo Nordisk Anti-Diabetic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.8 Sanofi
2.8.1 Business Overview
2.8.2 Anti-Diabetic Drugs Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Sanofi Anti-Diabetic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
2.9 Teva Pharmaceutical Industries
2.9.1 Business Overview
2.9.2 Anti-Diabetic Drugs Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Teva Pharmaceutical Industries Anti-Diabetic Drugs Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)
3 Global Anti-Diabetic Drugs Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)
3.1 Global Anti-Diabetic Drugs Sales and Market Share by Manufacturer (2016-2017)
3.2 Global Anti-Diabetic Drugs Revenue and Market Share by Manufacturer (2016-2017)
3.3 Market Concentration Rate
3.3.1 Top 3 Anti-Diabetic Drugs Manufacturer Market Share in 2017
3.3.2 Top 6 Anti-Diabetic Drugs Manufacturer Market Share in 2017
3.4 Market Competition Trend
4 Global Anti-Diabetic Drugs Market Analysis by Regions
4.1 Global Anti-Diabetic Drugs Sales, Revenue and Market Share by Regions
4.1.1 Global Anti-Diabetic Drugs Sales and Market Share by Regions (2013-2018)
4.1.2 Global Anti-Diabetic Drugs Revenue and Market Share by Regions (2013-2018)
4.2 North America Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
4.3 Europe Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
4.4 Asia-Pacific Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
4.5 South America Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
4.6 Middle East and Africa Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
5 North America Anti-Diabetic Drugs by Countries
5.1 North America Anti-Diabetic Drugs Sales, Revenue and Market Share by Countries
5.1.1 North America Anti-Diabetic Drugs Sales and Market Share by Countries (2013-2018)
5.1.2 North America Anti-Diabetic Drugs Revenue and Market Share by Countries (2013-2018)
5.2 United States Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
5.3 Canada Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
5.4 Mexico Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
6 Europe Anti-Diabetic Drugs by Countries
6.1 Europe Anti-Diabetic Drugs Sales, Revenue and Market Share by Countries
6.1.1 Europe Anti-Diabetic Drugs Sales and Market Share by Countries (2013-2018)
6.1.2 Europe Anti-Diabetic Drugs Revenue and Market Share by Countries (2013-2018)
6.2 Germany Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
6.3 UK Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
6.4 France Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
6.5 Russia Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
6.6 Italy Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
7 Asia-Pacific Anti-Diabetic Drugs by Countries
7.1 Asia-Pacific Anti-Diabetic Drugs Sales, Revenue and Market Share by Countries
7.1.1 Asia-Pacific Anti-Diabetic Drugs Sales and Market Share by Countries (2013-2018)
7.1.2 Asia-Pacific Anti-Diabetic Drugs Revenue and Market Share by Countries (2013-2018)
7.2 China Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
7.3 Japan Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
7.4 Korea Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
7.5 India Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
7.6 Southeast Asia Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
8 South America Anti-Diabetic Drugs by Countries
8.1 South America Anti-Diabetic Drugs Sales, Revenue and Market Share by Countries
8.1.1 South America Anti-Diabetic Drugs Sales and Market Share by Countries (2013-2018)
8.1.2 South America Anti-Diabetic Drugs Revenue and Market Share by Countries (2013-2018)
8.2 Brazil Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
8.3 Argentina Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
8.4 Colombia Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
9 Middle East and Africa Anti-Diabetic Drugs by Countries
9.1 Middle East and Africa Anti-Diabetic Drugs Sales, Revenue and Market Share by Countries
9.1.1 Middle East and Africa Anti-Diabetic Drugs Sales and Market Share by Countries (2013-2018)
9.1.2 Middle East and Africa Anti-Diabetic Drugs Revenue and Market Share by Countries (2013-2018)
9.2 Saudi Arabia Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
9.3 UAE Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
9.4 Egypt Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
9.5 Nigeria Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
9.6 South Africa Anti-Diabetic Drugs Sales and Growth Rate (2013-2018)
10 Global Anti-Diabetic Drugs Market Segment by Type
10.1 Global Anti-Diabetic Drugs Sales, Revenue and Market Share by Type (2013-2018)
10.1.1 Global Anti-Diabetic Drugs Sales and Market Share by Type (2013-2018)
10.1.2 Global Anti-Diabetic Drugs Revenue and Market Share by Type (2013-2018)
10.2 Biguanides Sales Growth and Price
10.2.1 Global Biguanides Sales Growth (2013-2018)
10.2.2 Global Biguanides Price (2013-2018)
10.3 Sulfonylureas Sales Growth and Price
10.3.1 Global Sulfonylureas Sales Growth (2013-2018)
10.3.2 Global Sulfonylureas Price (2013-2018)
10.4 Meglitinides Sales Growth and Price
10.4.1 Global Meglitinides Sales Growth (2013-2018)
10.4.2 Global Meglitinides Price (2013-2018)
10.5 Thiazolidinediones Sales Growth and Price
10.5.1 Global Thiazolidinediones Sales Growth (2013-2018)
10.5.2 Global Thiazolidinediones Price (2013-2018)
10.6 Dipeptidyl Peptidase IV Inhibitors Sales Growth and Price
10.6.1 Global Dipeptidyl Peptidase IV Inhibitors Sales Growth (2013-2018)
10.6.2 Global Dipeptidyl Peptidase IV Inhibitors Price (2013-2018)
10.7 α-Glucosidase Inhibitors Sales Growth and Price
10.7.1 Global α-Glucosidase Inhibitors Sales Growth (2013-2018)
10.7.2 Global α-Glucosidase Inhibitors Price (2013-2018)
11 Global Anti-Diabetic Drugs Market Segment by Application
11.1 Global Anti-Diabetic Drugs Sales Market Share by Application (2013-2018)
11.2 Type I Diabetes Sales Growth (2013-2018)
11.3 Type II Diabetes Sales Growth (2013-2018)
11.4 Others Sales Growth (2013-2018)
12 Anti-Diabetic Drugs Market Forecast (2018-2023)
12.1 Global Anti-Diabetic Drugs Sales, Revenue and Growth Rate (2018-2023)
12.2 Anti-Diabetic Drugs Market Forecast by Regions (2018-2023)
12.2.1 North America Anti-Diabetic Drugs Market Forecast (2018-2023)
12.2.2 Europe Anti-Diabetic Drugs Market Forecast (2018-2023)
12.2.3 Asia-Pacific Anti-Diabetic Drugs Market Forecast (2018-2023)
12.2.4 South America Anti-Diabetic Drugs Market Forecast (2018-2023)
12.2.5 Middle East and Africa Anti-Diabetic Drugs Market Forecast (2018-2023)
12.3 Anti-Diabetic Drugs Market Forecast by Type (2018-2023)
12.3.1 Global Anti-Diabetic Drugs Sales Forecast by Type (2018-2023)
12.3.2 Global Anti-Diabetic Drugs Market Share Forecast by Type (2018-2023)
12.4 Anti-Diabetic Drugs Market Forecast by Application (2018-2023)
12.4.1 Global Anti-Diabetic Drugs Sales Forecast by Application (2018-2023)
12.4.2 Global Anti-Diabetic Drugs Market Share Forecast by Application (2018-2023)
13 Sales Channel, Distributors, Traders and Dealers
13.1 Sales Channel
13.1.1 Direct Marketing
13.1.2 Indirect Marketing
13.1.3 Marketing Channel Future Trend
13.2 Distributors, Traders and Dealers
14 Research Findings and Conclusion
15 Appendix
15.1 Methodology
15.2 Data Source
List of Tables and Figures
Figure Anti-Diabetic Drugs Picture
Table Product Specifications of Anti-Diabetic Drugs
Figure Global Sales Market Share of Anti-Diabetic Drugs by Types in 2017
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
